<DOC>
	<DOCNO>NCT02410551</DOCNO>
	<brief_summary>The goal clinical research study learn give pacritinib standard care drug follow allogeneic stem cell transplant help control myeloproliferative neoplasm . The safety therapy also study .</brief_summary>
	<brief_title>Pacritinib Before Transplant Myeloproliferative Neoplasms ( MPN )</brief_title>
	<detailed_description>Study Drug Administration : If find eligible take part study , take pacritinib time day mouth , 2 time day . Your doctor tell start stop take pacritinib . You may able take drug 2-6 month depend tolerate drug transplant date . If receive transplant , may able continue take study drug long doctor think best interest . You must swallow capsule whole glass ( 8 ounce ) water . Do open , break , chew capsule . If vomit miss dose pacritinib , take next dose pacritinib regular time . Do `` make '' miss vomit dose . You give study drug diary write time take dose pacritinib . You need bring study drug diary , leftover study drug , empty study drug container study visit . The dose pacritinib receive may lower stop , doctor think need . About 21 day last dose pacritinib , give standard care drug allogeneic stem cell transplant . Your doctor explain treatment stem cell transplant detail . You require sign separate consent form . Study Visits : One ( 1 ) time month : - You physical exam . - Blood ( 2 teaspoon ) draw routine test check kidney liver function . - You electrocardiogram ( EKG -- test measure electrical activity heart ) . On Day 14 ( +/- 2 day ) Cycle 1 , blood ( 2 teaspoon ) draw routine test check kidney liver function . You blood draw local lab clinic closer home . The result send study doctor MD Anderson . During Week 2 Cycle 1 , member study staff call ask symptom may . This call last 5-10 minute . Length Study : You study 1 year transplant . You may take study early disease get bad , intolerable side effect , unable follow study direction . Your participation study 1 year follow-up test . End-of-Study Visit : Within 7 day last dose pacritinib , stem cell transplant : - You physical exam ultrasound , MRI , CT scan abdomen measure liver spleen . - You EKG . Before transplant , bone marrow biopsy/aspiration check status disease . Follow-Up Tests : You follow-up visit 1 , 3 , 6 , 12 month transplant : - You complete 3 questionnaire symptoms quality life . It take 20-30 minute complete questionnaire . - At Month 3 , physical exam ultrasound , MRI , CT scan abdomen measure liver spleen . This repeat Month 12 , doctor think need . - At Months 3 12 , bone marrow biopsy/aspiration check status disease . This investigational study . Pacritinib FDA approve commercially available . It currently use research purpose . The study doctor explain study drug design work . Up 40 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Patients Idiopathic Myelofibrosis Myelofibrosis secondary Polycythemia Vera Essential Thrombocythemia . 2 . Patients 18 year less equal 70 year . 3 . Patients want pursue transplant . 4 . Patients must Zubrod PS equal less 2 . 5 . Calculated creatinine clearance great 50ml/min . use CockcroftGault equation . 6 . Ejection fraction equal 40 % . 7 . Serum direct bilirubin le 1 mg/dl ( unless due Gilbert 's syndrome hemolysis ) . 8 . SGPT equal less 4 x normal value . 9 . Corrected DLCO equal 50 % expect . 10 . Negative Beta HCG test woman childbearing potential define postmenopausal 12 month previous surgical sterilization ) fertile , male female must agree use contraceptive . 1 . Patients low risk myelofibrosis . 2 . Uncontrolled lifethreatening infection . 3 . HIV positive . 4 . Patients active viral hepatitis . 5 . Prior treatment Pacritinib . 6 . Prior stem cell transplant . 7 . QTc great 450 ms. 8 . CYP3A4 strong moderate inhibitors/inducers past 7 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Myeloproliferative Diseases</keyword>
	<keyword>Myeloproliferative Neoplasms</keyword>
	<keyword>MPN</keyword>
	<keyword>Myelofibrosis</keyword>
	<keyword>Polycythemia vera</keyword>
	<keyword>PV</keyword>
	<keyword>Essential thrombocythemia</keyword>
	<keyword>Allogeneic stem cell transplantation</keyword>
	<keyword>Allo TP</keyword>
	<keyword>Pacritinib</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Questionnaires</keyword>
	<keyword>Surveys</keyword>
	<keyword>Phone call</keyword>
</DOC>